(NASDAQ: CLDX) Celldex Therapeutics's forecast annual revenue growth rate of 77.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Celldex Therapeutics's revenue in 2025 is $7,559,000.On average, 5 Wall Street analysts forecast CLDX's revenue for 2025 to be $219,432,967, with the lowest CLDX revenue forecast at $46,475,969, and the highest CLDX revenue forecast at $491,317,383. On average, 2 Wall Street analysts forecast CLDX's revenue for 2026 to be $507,915,944, with the lowest CLDX revenue forecast at $219,100,995, and the highest CLDX revenue forecast at $796,730,892.
In 2027, CLDX is forecast to generate $3,116,014,519 in revenue, with the lowest revenue forecast at $1,752,807,962 and the highest revenue forecast at $5,278,342,160.